Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
Key Highlights
- ➤IHL-42X DReAMzz trial enrolling approximately 120 patients across nine dose combinations
- ➤First-patient dosing underway at 14 U.S. sites; completion expected in mid-2027
- ➤IXHL unrestricted cash $68.4M as of September 24, supporting at least 12 months
- ➤IHL-675A Australian Phase 2 RA study terminated after recruitment challenges
- ➤PSX-001 remains IXHL's principal secondary clinical asset
Dallas, Texas--(Newsfile Corp. - October 1, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). IXHL's FY26 update moves the IHL-42X story from DReAMzz preparation into active clinical execution, with first-patient dosing underway and the balance sheet providing runway for at least 12 months of planned operations. The study is evaluating approximately 120 patients across nine dose combinations and 14 U.S. sites, with completion expected in mid-2027. In our view, the next several quarters should be measured primarily by enrollment cadence, dose optimization, and whether DReAMzz supports a more clearly defined Phase 3 design rather than near-term P&L trends. This sequencing should improve confidence in dose selection and Phase 3 trial design before IXHL commits to the higher development spending associated with late-stage studies.
Get started
Create a free account to read the full story.